Bay Breeze Senior Living And Rehabilitation Center | |
3387 Gulf Breeze Parkway, Gulf Breeze, Florida 32561 | |
(850) 932-9257 | |
Name | Bay Breeze Senior Living And Rehabilitation Center |
---|---|
Location | 3387 Gulf Breeze Parkway, Gulf Breeze, Florida |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 120 |
Occupancy Rate | 81.33% |
Medicare ID (CCN) | 105487 |
Legal Business Name | Fl Hud Baybreeze, Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1184616971 |
Organization Name | DELTA HEALTH GROUP INC |
Doing Business As | BAY BREEZE NURSING AND RETIREMENT CENTER |
Address | 3387 Gulf Breeze Pkwy, Gulf Breeze, FL 32563 |
Phone Number | 850-932-9257 |
News Archive
Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that new data from the PROTECT II study will be presented by William O'Neill, M.D., executive dean for clinical affairs at the University of Miami Miller School of Medicine, and principal investigator for the PROTECT II study, during the late-breaking clinical trials session at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Sessions in Baltimore, Maryland.
Researchers at Children's Hospital Los Angeles and The Saban Research Institute of CHLA have created a dynamic functional mouse model for lung injury repair, a tool that will help scientists explain the origins of lung disease and provide a system by which new therapies can be identified and tested.
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
During a conference in London Thursday, development officials urged world leaders to "accelerate efforts to meet the Millennium Development Goals (MDGs) by 2015 and [said] rich countries must make good on promises to boost aid to poorer nations," Reuters AlertNet reports.
› Verified 7 days ago
NPI Number | 1811157019 |
Organization Name | FL HUD BAYBREEZE, LLC |
Doing Business As | BAYBREEZE SENIOR LIVING AND REHABILITATION CENTER |
Address | 3387 Gulf Breeze Parkway, Gulf Breeze, FL 32563 |
Phone Number | 850-932-9257 |
News Archive
Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that new data from the PROTECT II study will be presented by William O'Neill, M.D., executive dean for clinical affairs at the University of Miami Miller School of Medicine, and principal investigator for the PROTECT II study, during the late-breaking clinical trials session at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Sessions in Baltimore, Maryland.
Researchers at Children's Hospital Los Angeles and The Saban Research Institute of CHLA have created a dynamic functional mouse model for lung injury repair, a tool that will help scientists explain the origins of lung disease and provide a system by which new therapies can be identified and tested.
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
During a conference in London Thursday, development officials urged world leaders to "accelerate efforts to meet the Millennium Development Goals (MDGs) by 2015 and [said] rich countries must make good on promises to boost aid to poorer nations," Reuters AlertNet reports.
› Verified 7 days ago
NPI Number | 1841944055 |
Organization Name | BAY BREEZE OPERATING INVESTMENTS LLC |
Address | 3387 Gulf Breeze Pkwy, Gulf Breeze, FL 32563 |
Phone Number | 954-300-3878 |
News Archive
Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that new data from the PROTECT II study will be presented by William O'Neill, M.D., executive dean for clinical affairs at the University of Miami Miller School of Medicine, and principal investigator for the PROTECT II study, during the late-breaking clinical trials session at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Sessions in Baltimore, Maryland.
Researchers at Children's Hospital Los Angeles and The Saban Research Institute of CHLA have created a dynamic functional mouse model for lung injury repair, a tool that will help scientists explain the origins of lung disease and provide a system by which new therapies can be identified and tested.
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
During a conference in London Thursday, development officials urged world leaders to "accelerate efforts to meet the Millennium Development Goals (MDGs) by 2015 and [said] rich countries must make good on promises to boost aid to poorer nations," Reuters AlertNet reports.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that new data from the PROTECT II study will be presented by William O'Neill, M.D., executive dean for clinical affairs at the University of Miami Miller School of Medicine, and principal investigator for the PROTECT II study, during the late-breaking clinical trials session at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Sessions in Baltimore, Maryland.
Researchers at Children's Hospital Los Angeles and The Saban Research Institute of CHLA have created a dynamic functional mouse model for lung injury repair, a tool that will help scientists explain the origins of lung disease and provide a system by which new therapies can be identified and tested.
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
During a conference in London Thursday, development officials urged world leaders to "accelerate efforts to meet the Millennium Development Goals (MDGs) by 2015 and [said] rich countries must make good on promises to boost aid to poorer nations," Reuters AlertNet reports.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $88595 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 22.8 | 14.46 |
Percentage of long-stay residents who lose too much weight | 15.33 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 29.81 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.9 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.28 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0.3 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.98 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 16.51 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.46 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 2.05 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 15.58 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 23.25 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 10.55 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
Percentage of short-stay residents who made improvements in function | 84.55 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.9 | 82.93 |
News Archive
Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that new data from the PROTECT II study will be presented by William O'Neill, M.D., executive dean for clinical affairs at the University of Miami Miller School of Medicine, and principal investigator for the PROTECT II study, during the late-breaking clinical trials session at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Sessions in Baltimore, Maryland.
Researchers at Children's Hospital Los Angeles and The Saban Research Institute of CHLA have created a dynamic functional mouse model for lung injury repair, a tool that will help scientists explain the origins of lung disease and provide a system by which new therapies can be identified and tested.
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
During a conference in London Thursday, development officials urged world leaders to "accelerate efforts to meet the Millennium Development Goals (MDGs) by 2015 and [said] rich countries must make good on promises to boost aid to poorer nations," Reuters AlertNet reports.
› Verified 7 days ago
Bay Breeze Senior Living And Rehabilitation Center Location: 3387 Gulf Breeze Parkway, Gulf Breeze, Florida 32561 Phone: (850) 932-9257 |